See All Categories

Learn More

GHPharm

For the health and happiness of humanity
GHPharm produces diverse R&D outcomes
Discover a healthier you!

Greetings from the CEO

Our goal at GHPharm is to make your future healthier and bring
happiness to your life today


We hope that all our customers are able to enjoy a happy and healthy life at a time when the average lifespan is reaching 100 years. We want you to live your life to the fullest rather than spend it fighting disease—all while staying happy and healthy until the age of 100 or even 150.
This is why GHPharm is always taking on new challenges.
The effects of the foods we have developed through our research can liberate our customers from refractory/intractable diseases and help them maintain healthy lives.
GHPharm is focusing all of its capabilities and technologies on the task of strengthening Korea’s foundational technologies to enable the development of new, original medicines.
We hope that you share our passion for our dreams and endeavors.
What we want most of all, however, is for you to lead a healthy life.
GHPharm aims to be a faithful companion in your efforts to maintain your current happiness and have a healthy future.

Gil Hong Park
CEO of GHPharm

Core capabilities

GHPharm’s core capabilities
illuminate our future


GHPharm develops new and original medicines and functional foods and cosmetics using naturally occurring substances (bracken (Pteridium aquilinum), royal Asian fern (Osmunda japonica), ginger (Zingiber officinale), etc.) and synthetic chemicals for the treatment of intractable chronic diseases, such as dementia, hair loss, arthralgia, rheumatoid arthritis, atopic dermatitis, and skin dryness.


GHPharm’s foundational technologies focus on discovering
new treatments through constant research and development


Bracken (called gosari in Korean) was traditionally a popular wild herb and known as “mountain-grown beef” for its wealth of nutrients and health benefits.
The pterosin found in bracken has been proven, through pre-clinical studies, to be effective in preventing and treating Alzheimer’s disease, degenerative arthritis, and the subsequently occurring arthralgia; improving the symptoms of diabetes and obesity; and alleviating hair loss. GHPharm has promoted the beneficial effects of bracken’s pterosin through articles published in esteemed medical journals both in Korea and overseas.
Because the process of removing the toxic substances that bracken contains also destroys pterosin, we had, until now, been unable to fully utilize bracken’s medicinal value. However, GHPharm has developed a foundational technology for safely extracting pterosin from bracken that is patent-registered in Korea (with patent applications submitted in the US, China, and EU).
Ginger has been used for thousands of years (recommended by the Ayurveda, a system of natural medicine developed in India, as an efficient remedy for osteoporosis) and continues to be used today. GHPharm discovered a substance in ginger, dehydrozingerone, that is an active ingredient in modern prevention/treatment methods for osteoporosis. Its effectiveness was proven through a pre-clinical study, the results of which were published in a major international journal. GHPharm has a registered patent for dehydrozingerone in Korea and has submitted patent applications for it in the US, China, and EU.
Osmunda japonica (known as Asian royal fern or gobi in Korean) was widely prescribed in Europe (especially northern Spain) as a remedy for rheumatoid arthritis, arthralgia, and bone fractures. Today, it is protected by law as an endangered species. In this plant, GHPharm discovered osmundacetone, an active ingredient for the treatment of bone diseases (e.g. rheumatoid arthritis), and published the results of its findings in a leading international journal. GHPharm has a registered patent for osmundacetone in Korea and has submitted patent applications for it in the US and China.









Timeline

2020


05: Gil Hong Park named as CEO
05: Company name changed to “GHPharm Co., Ltd.”
03: Signed joint development contract with Jirisan Dream for the development of a dementia-alleviating food (“Smart Jirisan bracken tea”)
01: Signed MOU with Gyeonggi-do Office and the Gyeonggido Business & Science Accelerator as a partner organization in research and biotechnology transfer for the expansion of biotechnologies and discovery of future growth engines
01: Received letter of intent from Baiyunjingkang (total: 7,000 beds) for clinical testing and joint commercialization activities


2019


10: Gained venture firm certification (from Korea Technology Finance Corporation)
09: Jae Sik Jeon named as CEO
06: Gil Hong Park named as CEO


2016


07: Signed research outsourcing contract with Korea University Medicine Industry-Academia Cooperative Group for the development of preventative/treatment medication for dementia and bone diseases
06: Jae Sik Jeon named as CEO
06: KOPHARM founded

GHPharm is leading the way
to a healthier and happier life.

Research on dementia

Patents


Patent registration number (Republic of Korea): 10-1934527·10-2085358
Patent application number (USA): 16/622,799
Patent application number (China): 201880038464.8
Patent application number (EU): 17913480.4-1109

A novel compound for the prevention or treatment of neurodegenerative diseases that is comprised of new chemicals and/or includes such new chemicals as the active ingredient Republic of Korea Patent Registration Number: 10-1934527


Date registered: December 26, 2018
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

A novel compound for the prevention or treatment of neurodegenerative diseases that is comprised of pterosin compounds and/or their derivatives Republic of Korea Patent Registration Number: 10-2085358


Date registered: February 3, 2020
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

Research on hair loss prevention and hair growth promotion

Patents


Patent application number (Republic of Korea): 10-2020-0050364

A novel compound for the prevention of hair loss and/or promotion of hair growth that is comprised of pterosin compounds and/or their derivatives Republic of Korea Patent Application Number: 10-2020-0050364


Date registered: April 24, 2020
Assignees: GHPharm Co., Ltd., Korea University Research and Business Foundation
Main inventor: Gil Hong Park

Research on rheumatoid arthritis, arthralgia,
bone fracture

Patents


Patent registration number (Republic of Korea):10-1848489
Patent application number (USA) 16/338,354
Patent application number (China): 2019082600580310

A compound for the prevention or treatment of bone diseases that includes osmundacetone or a salt that is able to pharmaceutically tolerate osmundacetone Republic of Korea Patent Registration Number: 10-1848489


Date registered: April 6, 2018
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Korea Institute of Radiological & Medical Sciences
Main inventor: Gil Hong Park

Research on osteoporosis

Patents


Patent registration number (Republic of Korea):10-2114197
Patent application number (USA) 16/620,847
Patent application number (China): 2019122100014010
Patent application number (EU): 18837846.7

New dibenzylideneacetone derivative and its use Republic of Korea Patent Application Number: 10-2114197


Date registered: May 18, 2020
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

Research on atopic dermatitis, xeroderma

Patents


Patent application number (Republic of Korea): 10-2018-0098863

A pharmaceutical compound for the prevention or treatment of atopic dermatitis or xeroderma (dry skin) that includes dihydroxybenzoic acid derivatives Republic of Korea Patent Application Number: 10-2018-0098863


Date registered: August 23, 2018
Assignees: GHPharm Co., Ltd., Korea University Research and Business Foundation, BIOGENOKOREA Co., Ltd.
Main inventor: Gil Hong Park

Research on COVID-19

Patents


Patent application number(Republic of Korea): 10-2020-0099490

Composition for preventing or treating RNA virus
infectious disease comprising Pteridium aquilinum extract or fraction thereof


Bracken water extract has been proven to have activated antiviral capabilities, as can be seen in its patented use by a research center (Registered patent (Korea): 10-2124592) in an independently-developed hand sanitizer.
The patents that are currently registered in China (CN102166276B, CN105125864A) confirm the existence of an antiviral substance in the organic extract (which includes bracken).

Contact Us!


※ Unauthorized reproduction or theft is prohibited by the Copyright Act (article 97.5).
The copyright of the work is in our company and will be punished in case of violation.

Copyright © 2020 LuLuLaLa Lab. All rights reserved.

WORLD SHIPPING

PLEASE SELECT THE DESTINATION COUNTRY AND LANGUAGE :

GO
close